Key result
Thrombopoietin synergizes with other agonists to potentiate the protein-kinase-C-mediated activation of the ERK pathway in human platelets.
Why the study?
Does thrombopoietin potentiate the ERK activation pathway in human platelets?
Population
Human platelets
Comparison
Thrombopoietin alone or in combination with… vs Agonists alone or no TPO
Design
Preclinical
Authors
Loading...
May modulate cytoskeletal over aggregatory platelet responses; leaves open clinical relevance in humans.
Does thrombopoietin potentiate the ERK activation pathway in human platelets?
Thrombopoietin synergizes with other agonists to potentiate the ERK activation pathway in human platelets, which may regulate cytoskeletal functions rather than primary aggregation.
Ezumi et al. (1998) studied this question. Thrombopoietin (TPO) was evaluated on ERK activation pathway. Thrombopoietin synergizes with other agonists to potentiate the protein-kinase-C-mediated activation of the ERK pathway in human platelets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: